Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Genomförbarhetsutvärdering av Muse Magnetic Resonance Guided Focused Ultrasound System (BreastMRgFUS)

19 november 2026 uppdaterad av: University of Utah

En genomförbarhetsutvärdering av Muse Magnetic Resonance Guided Focused Ultrasound System

This is an open-label, single arm, single center, non-randomized feasibility study of the Muse MRgFUS System in subjects with breast cancer. Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or multicentric disease) followed by surgical resection per standard of care. The partial tumor ablation design will ensure that no information is lost that would impact the subject's standard of clinical care. Because current care often includes testing on the tumor, retaining a portion of viable tumor is advised by the clinical team. To ensure viable tissue confirmation, patients will be enrolled in two cohorts as described in the protocol. The investigators will use imaging correlation, histological evaluation, and subject reported outcomes to assess the safety, tolerability, and efficacy of the Muse MRgFUS System. This proposed study will adhere to the guidelines of subjects receiving a timely tumor resection after diagnosis. All subjects will undergo the definitive procedure of surgical resection per standard of care. Surgical resection cannot be delayed as a result of the ablation and should occur within 6 weeks after the decision to proceed with surgical resection. In cases where a surgery may occur outside of the 6 week window, prior approval from the external DSMC should be obtained. While MRgFUS ablation is designed to be a breast-conserving technique, the investigators will enroll patients that are undergoing any surgical resection, including both lumpectomy or mastectomy. Both surgical procedures will allow assessment of the defined primary, secondary and exploratory objectives.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

34

Fas

  • Tidig fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Subject is able to speak and understand English.

  • Female subjects 18 years of age or older with invasive breast cancer undergoing surgery

  • ECOG < 2.

  • ASA (American Society of Anesthesiologists) Physical Status Classification Scale assessment of I-II.

  • Adequate breast size for MUSE device assessed by physician prior to study enrollment.

  • Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

  • Adequate Renal Function defined as an eGFR > 30 mL/min/1.73.

  • Female subjects of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.

  • Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization (i.e. bilateral oophorectomy, bilateral salpingectomy, or hysterectomy). The post-menopausal status will be defined as having been amenorrhoeic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:

    • Women < 50 years of age:

      ---Amenorrhoeic for ≥ 12 months following cessation of exogenous hormonal treatments; and

      ----Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution.

    • Women ≥ 50 years of age:

      • Amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments; or
      • Had radiation-induced menopause with last menses >1 year ago; or
      • Had chemotherapy-induced menopause with last menses >1 year ago.

Exclusion Criteria:

  • Receiving other investigational agents at the time of study registration.
  • Prior systemic anti-cancer therapy or any investigational therapy for neoadjuvant treatment of breast cancer.
  • Prior radiation therapy to the ipsilateral breast or radiation whose field(s) encompassed the breast within which the current diagnosis of cancer is made.
  • The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, or bladder or of the cervix). Low risk malignancies may be allowed after discussion with PI and medical monitor.
  • Women with breast implants
  • Pregnant or lactating women
  • Inability to lie prone for 90 minutes as reported by patient or determined by investigator assessment.
  • Known prior adverse reaction or allergy to commonly used sedatives (i.e. versed, propofol) (NCI CTCAE v5.0 Grade ≥ 3).
  • Known prior adverse reaction or allergy to gadolinium contrast (NCI CTCAE v5.0 Grade ≥ 3).
  • Contraindication to MRI as determined by treating physician or patient response on MRI patient history and safety questionnaire (Appendix 4)
  • Medical, psychiatric, cognitive, or other conditions in the opinion of the investigator that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.

Additional Exclusion Criteria for Cohort 1 patients only

  • Patient's tumor is grade 3 as determined in consultation with pathologist and treating physician.
  • The amount of invasive tumor in the core biopsy specimen is small as determined in consultation with pathologist and treating physician.
  • Core biopsy result is equivocal for HER2 after testing by both in situ hybridization and immunohistochemistry.
  • There is doubt about the handling of the core biopsy specimen (long ischemic time, short time in fixative, different fixative), or the test is suspected by the pathologist to be negative on the basis of testing error.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Muse MRgFUS System

Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or multicentric disease) followed by surgical resection per standard of care.

The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by type
Tidsram: 2 months

evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events

2 months
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by severity (as defined by the NCI CTCAE, version 5.0)
Tidsram: 2 months

evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events

2 months
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by seriousness
Tidsram: 2 months

evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events

2 months
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by duration
Tidsram: 2 months

evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events

2 months
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by relationship to the investigational intervention reported during and after the procedure as compared to baseline
Tidsram: 2 months

evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events

2 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Evaluate ablation efficacy by pathologic assessment
Tidsram: 1 month

estimate ablation efficacy

1 month
Disease-free survival (DFS) as defined as the time from the date of ablation to the date of first recurrence or death from any cause
Tidsram: 5 years

estimate disease-free survival (DFS) at 5 years post ablation

5 years
Overall survival (OS) as defined as the time from registration until death from any cause
Tidsram: 5 years

estimate overall survival in this study population at 5 years post ablation

5 years
Evaluate ablation efficacy by MRI treatment assessment metrics of thermal dose
Tidsram: 1 month

estimate ablation efficacy

1 month
Evaluate ablation efficacy by T1-weighted non-perfused volume.
Tidsram: 1 month

estimate ablation efficacy

1 month
Evaluate how heat-induced pathways effect associations between vascular organization and immune cell infiltration.
Tidsram: 5 years

Analysis via bulk RNA sequencing data

5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Cindy Matsen, MD, Huntsman Cancer Institute

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 januari 2023

Primärt slutförande (Beräknad)

1 januari 2027

Avslutad studie (Beräknad)

1 augusti 2028

Studieregistreringsdatum

Först inskickad

2 mars 2022

Först inskickad som uppfyllde QC-kriterierna

11 mars 2022

Första postat (Faktisk)

22 mars 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

19 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • HCI148669

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera